Serum levels of irisin and nesfatin-1 in multiple sclerosis

Basit Öğe Kaydı
dc.contributor.authorAltas, Mustafa
dc.contributor.authorUca, Ali Ulvi
dc.contributor.authorAkdag, Turan
dc.contributor.authorOdabas, Faruk Omer
dc.contributor.authorTokgoz, Osman Serhat
dc.date.accessioned2024-02-23T14:30:06Z
dc.date.available2024-02-23T14:30:06Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractBackground: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. Objective: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing-remitting MS (RRMS). Methods:A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed.Results:Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z:-3.82, p<0.001; z:-4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. Conclusion: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis.en_US
dc.identifier.doi10.1590/0004-282X-ANP-2020-0520
dc.identifier.endpage167en_US
dc.identifier.issn0004-282X
dc.identifier.issn1678-4227
dc.identifier.issue2en_US
dc.identifier.pmid35195223en_US
dc.identifier.scopus2-s2.0-85128159791en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage161en_US
dc.identifier.urihttps://doi.org/10.1590/0004-282X-ANP-2020-0520
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15014
dc.identifier.volume80en_US
dc.identifier.wosWOS:000759823800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Arquivos Neuro- Psiquiatriaen_US
dc.relation.ispartofArquivos De Neuro-Psiquiatriaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectIrisinen_US
dc.subjectNesfatin-1en_US
dc.subjectInflammationen_US
dc.subjectApoptosisen_US
dc.subjectOxidative Stressen_US
dc.titleSerum levels of irisin and nesfatin-1 in multiple sclerosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu